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Glioblastoma (GBM) remains prognostically dismal, with
care centered on resection, motivating research into novel
therapies. Although inducing anti-tumor immunity
remains an attractive target for therapeutic and preventa-
tive intervention, the interplay between evolving dysregu-
lation of the glioma microenvironment and T cell
inefficacy remains poorly understood. In our murine
model of proneural glioma, retroviral delivery of PDGF
and cre-mediated knockout of PTEN in glial progenitors
of adult C57BL/6 gives rise to slow-growing tumors,
which were harvested at early- mid- and late-stage pro-
gression timepoints following induction, along with per-
ipheral blood. From human patients, tissue from low- and
high-grade glioma resections and corresponding periph-
eral lymphocytes were cryofrozen during surgery at New
York Presbyterian-CUMC. For both species, we employed
a commercially available primer set (iRepertoire) for
nested PCR of the complementarity-determining region 3
(CDR3) of the TCR-alpha and TCR-beta chains from the
T cell RNA, followed by next-generation sequencing on
an Illumina MiSeq. We developed a computational pipe-
line for mapping TCR cassettes, in silico translation, pair-
wise analysis of tissue/periphery per subject, and error
analysis. In the murine model, we observe that at late-
stage, the intratumoral TCR repertoire diverges signifi-
cantly from the peripheral, including dramatic expansion
of single tumor-associated CDR3s, while the peripheral
repertoire itself diverges from those of healthy mice. In
both human patients and mice, we observed tumor-asso-
ciated CDR3s, disproportionately abundant in tumor tis-
sue compared to the corresponding peripheral blood, at
both the amino acid and nucleotide level. In human sam-
ples we observed tumor-specific TCR expansions that
were associated with particular functional subsets (CD8+,
CD4+, Treg, NKT). Sequence-level study of the TCR
repertoire promises new insight into the scope of glioma
immunosuppression, especially systemic effects which
remain elusive and the origins of intratumoral suppressive
populations, and holds the potential for immunotherapeu-
tic interventions, non-invasive diagnostics, and direct
assessment of global responses to immunotherapy.
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